EP
KRYS icon

Essential Partners’s Krystal Biotech KRYS Stock Holding History

Essential Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49K Hold
4
– – ﹤0.01% 2088
2026
Q1 		$1.03K Hold
4
– – ﹤0.01% 2239
2025
Q4 		$986 Hold
4
– – ﹤0.01% 2034
2025
Q3 		$706 Buy
4
+3
+300% +$449 ﹤0.01% 2119
2025
Q2 		$137 Buy
+1
New +$147 ﹤0.01% 2026

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Essential Partners's KRYS Position: Q2 2026 in Review

Essential Partners held its Krystal Biotech (KRYS) position steady in Q2 2026 at 4 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Essential Partners first reported a position in KRYS in Q2 2025 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Essential Partners held 4 shares of Krystal Biotech worth $1.49K as of Q2 2026.
  • Essential Partners left its Krystal Biotech share count unchanged in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2088 holding.
  • Essential Partners first reported a position in Krystal Biotech in Q2 2025 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.